New hope for Hard-to-Treat cancers? early trial launches for BHV-1510

NCT ID NCT06384807

Recruiting now Disease control Sponsor: Biohaven Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because it is a first-in-human trial, the main focus is on safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BHV-1510 (a drug) given alone or with cemiplimab (another drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early first-in-human study, so safety and effectiveness are not yet known. Many experimental cancer drugs fail in early testing, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site-101
RECRUITING

St Louis, Missouri, 63108, United States
Site-102
RECRUITING

Fairfax, Virginia, 22031, United States
Site-103
RECRUITING

Miami, Florida, 33176, United States
Site-104
RECRUITING

Dallas, Texas, 75231, United States
Site-105
RECRUITING

Orlando, Florida, 32827, United States
Site-106
RECRUITING

West Valley City, Utah, 84119, United States
Site-107
RECRUITING

Nashville, Tennessee, 37203, United States
Site-108
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Site-109
RECRUITING

Detroit, Michigan, 48201, United States
Site-110
RECRUITING

Augusta, Georgia, 30912, United States
Site-111
RECRUITING

Palo Alto, California, 94304, United States
Site-112
RECRUITING

La Jolla, California, 92093, United States
Site-113
RECRUITING

Duarte, California, 91010, United States
Site-114
RECRUITING

Washington D.C., District of Columbia, 20016, United States
Site-115
RECRUITING

Tampa, Florida, 33612, United States
Site-116
RECRUITING

Oklahoma City, Oklahoma, 73117, United States
Site-117
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.